Trevi Therapeutics (TRVI) Set to Announce Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Trevi Therapeutics to post earnings of ($0.09) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trevi Therapeutics Stock Performance

TRVI opened at $3.02 on Friday. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The company has a fifty day simple moving average of $3.03 and a 200 day simple moving average of $2.04.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TRVI. Oppenheimer reissued an “outperform” rating and issued a $9.00 target price on shares of Trevi Therapeutics in a research note on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 9th.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.